Gift Opening
$200 Off MarketBeat All Access
Thanks for being one of our best subscribers! You are eligible for a limited-time discount.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
Claim Your Discount
×
Free Trial

Integer (ITGR) Stock Forecast & Price Target

$130.43
+0.01 (+0.01%)
(As of 10/18/2024 ET)

Integer - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
1
Buy
6

Based on 7 Wall Street analysts who have issued ratings for Integer in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 7 analysts, 1 has given a hold rating, and 6 have given a buy rating for ITGR.

Consensus Price Target

$138.71
6.35% Upside
According to the 7 analysts' twelve-month price targets for Integer, the average price target is $138.71. The highest price target for ITGR is $150.00, while the lowest price target for ITGR is $130.00. The average price target represents a forecasted upside of 6.35% from the current price of $130.43.

ITGR Analyst Ratings Over Time

TypeCurrent Forecast
10/21/23 to 10/20/24
1 Month Ago
9/21/23 to 9/20/24
3 Months Ago
7/23/23 to 7/22/24
1 Year Ago
10/21/22 to 10/21/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
6 Buy rating(s)
6 Buy rating(s)
6 Buy rating(s)
3 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
2 Hold rating(s)
3 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$138.71$133.86$128.88$93.83
Forecasted Upside6.35% Upside3.61% Upside-0.25% Downside30.32% Upside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy

ITGR Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ITGR Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Integer Stock vs. The Competition

TypeIntegerMedical CompaniesS&P 500
Consensus Rating Score
2.86
2.79
2.50
Consensus RatingModerate BuyModerate BuyHold
Predicted Upside6.35% Upside13,587.63% Upside6.20% Upside
News Sentiment Rating
Positive News

See Recent ITGR News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
10/15/2024KeyCorp
3 of 5 stars
 Boost TargetOverweight ➝ Overweight$139.00 ➝ $144.00+8.74%
10/14/2024Truist Financial
2 of 5 stars
R. Newitter
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetBuy ➝ Buy$145.00 ➝ $150.00+14.24%
10/2/2024Benchmark
2 of 5 stars
 Reiterated RatingBuy ➝ Buy$130.00 ➝ $130.00+2.16%
10/1/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$124.00 ➝ $130.00+1.01%
10/1/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$135.00 ➝ $145.00+12.10%
7/16/2024Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$135.00+12.62%
Man behind OpenAI makes shocking new bet (Ad)

Billionaire Sam Altman has become one of the most powerful men in the world by running OpenAI… But there’s a far lesser known investment he’s making that could put OpenAI to shame. In fact this Sam Altman-backed company could actually become a crucial partner for OpenAI… And the US Military… not to mention hundreds of other giant companies around the globe. To make the story even crazier… this company only recently became viable, thanks to an obscure piece of legislation that President Trump signed before he left office… Which ordered the government to take this incredible new technology seriously.

3/14/2024CL King
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$137.00+20.30%
7/28/2023Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetEqual Weight$87.00 ➝ $94.00+0.52%
2/24/2023Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOverweight$85.00+15.18%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 12:34 AM ET.


ITGR Forecast - Frequently Asked Questions

According to the research reports of 7 Wall Street equities research analysts, the average twelve-month stock price forecast for Integer is $138.71, with a high forecast of $150.00 and a low forecast of $130.00.

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Integer in the last year. There is currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ITGR shares.

According to analysts, Integer's stock has a predicted upside of 6.35% based on their 12-month stock forecasts.

Integer has been rated by research analysts at Bank of America, Benchmark, Citigroup, KeyCorp, and Truist Financial in the past 90 days.

Analysts like Integer more than other "medical" companies. The consensus rating score for Integer is 2.86 while the average consensus rating score for "medical" companies is 2.79. Learn more on how ITGR compares to other companies.


This page (NYSE:ITGR) was last updated on 10/20/2024 by MarketBeat.com Staff
From Our Partners